Clinical efficacy of combined therapy in children with stage 4 neuroblastoma.
10.7499/j.issn.1008-8830.2203049
- Author:
Wei-Ling LIANG
;
Xiao-Fan YE
;
Gong ZHONG
;
Jian-Jun CHEN
;
Kang-Lin DAI
1
;
Ka Leung Daniel CHEUK
;
Shu MO
;
Bo-Shen WANG
;
Chun-Yu LI
;
Xuan-Zhu JIANG
;
Zhi-Yuan XU
;
Li ZHOU
;
Irene CHAN
;
Jian-Liang CHEN
;
Patrick CHU
;
Pui Wah Pamela LEE
;
Chi Fung Godfrey CHAN
Author Information
1. Department of Pediatrics, Hong Kong University-Shenzhen Hospital, Shenzhen, Guangdong 518000, China.
- Publication Type:Journal Article
- Keywords:
Ch14.18/CHO;
Child;
Hematopoietic stem cell transplantation;
Neuroblastoma
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Child;
Child, Preschool;
Combined Modality Therapy;
Humans;
Infant;
Neuroblastoma/drug therapy*;
Positron-Emission Tomography;
Radionuclide Imaging;
Retrospective Studies;
Treatment Outcome
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(7):759-764
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the early clinical efficacy of combined therapy of stage 4 neuroblastoma.
METHODS:A retrospective analysis was performed on the medical data and follow-up data of 14 children with stage 4 neuroblastoma who were diagnosed in Hong Kong University-Shenzhen Hospital from January 2016 to June 2021.
RESULTS:The median age of onset was 3 years and 7.5 months in these 14 children. Among these children, 9 had positive results of bone marrow biopsy, 4 had N-Myc gene amplification, 13 had an increase in neuron-specific enolase, and 7 had an increase in vanilmandelic acid in urine. Based on the results of pathological examination, differentiated type was observed in 6 children, undifferentiated type in one child, mixed type, in one child and poorly differentiated type in 6 children. Of all the children, 10 received chemotherapy with the N7 regimen (including 2 children receiving arsenic trioxide in addition) and 4 received chemotherapy with the Rapid COJEC regimen. Thirteen children underwent surgery, 14 received hematopoietic stem cell transplantation, and 10 received radiotherapy. A total of 8 children received Ch14.18/CHO immunotherapy, among whom 1 child discontinued due to anaphylactic shock during immunotherapy, and the other 7 children completed Ch14.18/CHO treatment without serious adverse events, among whom 1 child was treated with Lu177 Dotatate 3 times after recurrence and is still undergoing chemotherapy at present. The median follow-up time was 45 months for all the 14 children. Four children experienced recurrence within 2 years, and the 2-year overall survival rate was 100%; 4 children experienced recurrence within 3 years, and 7 achieved disease-free survival within 3 years.
CONCLUSIONS:Multidisciplinary combined therapy is recommended for children with stage 4 neuroblastoma and can help them achieve better survival and prognosis.
